ADXN: יחס שווי שוק להכנסות החברה Addex Therapeutics Ltd.

The rise in the Addex Therapeutics (ADXN) share price is driven by breakthroughs in Parkinson's disease therapy and patents. A reliable raw material supplier network ensures the continuity of testing. The company's average P/S reflects the business valuation trend, with the indicator currently standing at 56.40. The financial model relies on grants and payments from global pharma partners for the development of innovative small molecules.

To build a high-quality portfolio, I utilize the P/S ratio, which determines the market value of a single dollar of revenue, allowing for an assessment of the business premium regardless of current profitability. In the case of Addex Therapeutics (ADXN), which focuses on R&D and the search for strategic partners, the P/S history reflects market expectations for the commercialization of allosteric modulators relative to actual sales volumes.